纳米抗体应用于感染疾病的研究现状  

Application of nanobodies in infectious diseases

作　　者：王志明[1] 杨立霞[1] WANG Zhi-ming;YANG Li-xia(NCPC New Drug Research and Development Co., Ltd., State Key Laboratory of Antibody Drug Development, Shijiazhuang 050015, Hebei Province, China)

机构地区：[1]华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室,河北石家庄050015

出　　处：《中国生物制品学杂志》2018年第5期563-568,共6页Chinese Journal of Biologicals

基　　金：国家"重大新药创制"科技重大专项(2014ZX09201041);河北省科技计划项目(16272401D)资助项目

摘　　要：纳米抗体独特的分子特性使其适用于疾病诊断治疗的许多不同领域。抗病毒、细菌、寄生虫感染以及毒素中和等应用领域的纳米抗体正处于不同的研发阶段。研发中的纳米抗体不仅以病原体表面抗原为靶点,调动宿主免疫系统的补体固定和调理吞噬杀伤来清除病原体,而且中和病原体产生的毒素,显著降低对宿主细胞结构和功能的损害作用,降低感染的严重程度。抗体工程技术突飞猛进的发展,推动了抗感染纳米抗体的探索及尝试。临床试验中的2个抗病毒纳米抗体均处于试验后期阶段,相关结果尚需进一步观察。不断的研究和推进或将使纳米抗体在未来的感染疾病应用中占据一席之地。Given the unique molecular characteristics,nanobodies are amenable to many applicability as diagnostic or therapeutic tools. These nanobodies have been exploited in the field of infectious diseases：the nanobodies of anti-virus,anti-bacteria,anti-parasites and detoxifying agents are in different stages of development. The key activities of the nanobodies targeting the pathogen surface targets are engagement of the host immune system through complement fixation and opsonophagocytic killing（OPK）,and neutralizing the toxin produced by the pathogen,which significantly reduce the damage to the structure and function of host cells,and reduce the severity of infection. The rapid development of antibody engineering technology promotes the exploration and new attempts in anti-infectious nanobodies. Two nanobody drugs have been in the late phase of clinical trials,of which the relevant results need to be further observed. Nanobodies may play a role in the treatment of infectious diseases with the promoting of research progress in the future.

关 键 词：纳米抗体 感染性疾病 胞内抗体 转移抗体 非洲锥虫病 解毒剂 

分 类 号：R392-33[医药卫生—免疫学]